Abstract

Historically, varicella has been a disease predominantly affecting preschool and school-aged children in the United States. The live attenuated varicella vaccine was licensed in this country in 1995 and has been recommended for routine use in immunization of children 12 to 18 months of age. As an increasing proportion of the children in the United States are protected from varicella by vaccination, changes in the current epidemiology of the disease are anticipated. This article reviews the current epidemiology of VZV infection and outlines issues related to possible changes in varicella epidemiology that may follow widespread use of the live varicella (Oka) vaccine.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.